Author/Authors :
Gholizadeh Narges نويسنده Assistant Professor, Department of Oral Medicine, School of Dentistry, Tehran University of Medical Sciences. Tehran, Iran , Mehdipour Masoumeh نويسنده Department of Oral and Maxillofacial Medicine, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran , Chavoshi Seyyed Hadi نويسنده Hematology and Oncology Research Center, Faculty of Medicine,Tabriz University of Medical Sciences, Tabriz, Iran , Kahani Sirvan نويسنده Faculty of Dentistry, Tabriz University of Medical Sciences, Tabriz, Iran , Sadrzadeh-Afshar Maryam-Sadat نويسنده Department of Oral and Maxillofacial Medicine,Faculty of Dentistry, Kashan University of Medical Sciences, Kashan, Iran
Abstract :
[Background]Oral mucositis is a frequent yet serious adverse event associated with chemotherapy in acute myeloid leukemia. Although a wide spectrum of drugs has been tested for prophylaxis of oral mucositis, few of them are satisfactory. There is currently substantial clinical interest in zinc (Zn) as an antioxidant and a protective agent against chemotherapy -relatednormal tissue injury. Therefore, in the present study, we investigated whether zinc prevents oral mucositis associated with chemotherapy in patients with AML.[Methods]A total of 140patients with AML were randomly selected and divided into two groups where the case groups received zinc sulfate 220 mg orally and the control groups received placeboes 3 times a day during their chemotherapy course. Data were analyzed by SPSS version 15 software. Mann-Whitney U test was used to evaluate mucositis, and pain intensity.[Results]The incidence rates of mucositis were all markedly lower in oral zinc sulfate group than in control (P = 0.004).[Conclusions]Zinc is available for preventing the complications of oral mucositis, and thus for improving patient quality of life.
